Drugs / FP-02.2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02496897 | Jul 2015 → Oct 2017 | hepatitis B virus infection | Altimmune, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FP-02.2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02496897 ↗ |
| Route | Intramuscular | “A low dose (150 µg/peptide) of the FP-02.2 vaccine administered by IM injection on Days 1, 29, and 57.” NCT02496897 ↗ |